Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism
Authors:
- Norah G. VerboutNVNorah G. Verbout
- Jesse K. LortonJLJesse K. Lorton
- David B. JacobyDJDavid B. Jacoby
- Allison D. FryerAFAllison D. Fryer
- 1 May 2007
- journal article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (5) , L1126-L1135
Abstract
Airway hyperreactivity in antigen-challenged animals is mediated by eosinophil major basic protein (MBP) that blocks inhibitory M2muscarinic receptors on parasympathetic nerves, increasing acetylcholine release onto M3muscarinic receptors on airway smooth muscle. Acutely, anticholinergics block hyperreactivity in antigen-challenged animals and reverse asthma exacerbations in the human, but are less effective in chronic asthma. We tested whether atropine, given before antigen challenge, affected hyperreactivity, M2receptor function, eosinophil accumulation, and activation. Sensitized guinea pigs received atropine (1 mg/kg ip) 1 h before challenge and 6 h later. Twenty-four hours after challenge, animals were anesthetized, vagotomized, paralyzed, and ventilated. Airway reactivity to electrical stimulation of the vagi and to intravenous acetylcholine was not altered by atropine pretreatment in nonsensitized animals, indicating that atropine was no longer blocking postjunctional muscarinic receptors. Antigen challenge induced airway hyperreactivity to vagal stimulation that was significantly potentiated by atropine pretreatment. Bronchoconstriction induced by acetylcholine was not changed by antigen challenge or by atropine pretreatment. M2receptor function was lost in challenged animals but protected by atropine pretreatment. Eosinophils in bronchoalveolar lavage and within airway tissues were significantly increased by challenge but significantly reduced by atropine pretreatment. However, extracellular MBP in challenged airways was significantly increased by atropine pretreatment, which may account for reduced eosinophils. Depleting eosinophils with antibody to IL-5 before challenge prevented hyperreactivity and significantly reduced MBP in airways of atropine-pretreated animals. Thus atropine pretreatment potentiated airway hyperreactivity by increasing eosinophil activation and degranulation. These data suggest that anticholinergics enhance eosinophil interactions with airway nerves.Keywords
This publication has 64 references indexed in Scilit:
- Anticholinergic agents in asthma and COPDEuropean Journal of Pharmacology, 2006
- Eosinophil-Granule Major Basic Protein, a C-Type Lectin, Binds Heparin,Biochemistry, 2005
- Urinary 3‐bromotyrosine and 3‐chlorotyrosine concentrations in asthmatic patients: lack of increase in 3‐bromotyrosine concentration in urine and plasma proteins in aspirin‐induced asthma after intravenous aspirin challengeClinical & Experimental Allergy, 2004
- Leukemia inhibitory factor is synthesized and released by human eosinophils and modulates activation state and chemotaxisJournal of Allergy and Clinical Immunology, 1999
- Nerve growth factor is preformed in and activates human peripheral blood eosinophilsJournal of Allergy and Clinical Immunology, 1998
- How long should Atrovent be given in acute asthma?Thorax, 1998
- In vivo neutralization of eosinophil-derived major basic protein inhibits antigen-induced bronchial hyperreactivity in sensitized guinea pigs.Journal of Clinical Investigation, 1996
- Biochemical properties, activities, and presence in biologic fluids of eosinophil granule major basic proteinJournal of Allergy and Clinical Immunology, 1994
- Ipratropium bromide in acute asthma.BMJ, 1981
- Antiserum to the major basic protein of guinea pig eosinophil granulesImmunochemistry, 1976